Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG) announced the closing of its initial public offering on May 4, 2026, raising approximately USD 346.7 million in gross proceeds on the Nasdaq Global Select Market. The clinical-stage biotechnology company, headquartered in Cambridge, Massachusetts and Copenhagen, Denmark, began trading under the ticker symbol "COAG" on May 1, 2026.
The offering comprised 19,262,500 shares of common stock priced at USD 18.00 per share, including 2,512,500 shares issued upon the full exercise of the underwriters' option to purchase additional shares. Goldman Sachs & Co. LLC, Jefferies, and Evercore ISI acted as joint book-running managers, with Wedbush PacGrow serving as lead manager.
Hemab is developing therapies for rare blood coagulation disorders. Its lead asset, sutacimig (HMB-001), is a bispecific antibody in Phase I/II clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. Sutacimig has received Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation from the US FDA for the Glanzmann thrombasthenia indication, as well as Orphan Drug Designation from the European Medicines Agency and an Innovative Licensing and Access Pathway designation from the UK MHRA. The company's second clinical asset, HMB-002, is a monovalent antibody in Phase I/II development for the prophylactic treatment of Von Willebrand disease, and has received Fast Track Designation and Orphan Drug Designation from the FDA, as well as an ILAP designation from the UK MHRA.